Sanara MedTech Inc.

Good morning and welcome to the Cenara MedTech, Inc. first quarter 2023 results and business update conference call. At this time, all participants are on the listen-only mode. After management's prepared remarks, there will be a question and answer session. I would now like to turn the call over to Callan Nichols. Please go ahead.

Thank you and good morning, everyone. I'd like to welcome you to Cenara MedTech's earnings conference call for the quarter ended March 31st, 2023. We issued our earnings release yesterday afternoon, and I would like to highlight that we've posted today's deck on the investor relations page of our website. This supplemental deck, as well as a copy of our earnings release and the form 10-Q for the quarter ended March 31st, 2023, are available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, Executive Chairman, Zach Fleming, Chief Executive Officer, and Mike McNeil, Chief Financial Officer, to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call and our press release and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risks and uncertainties involving forward-looking statements and factors that could cause actual results, to vary materially from those projected or implied by forward-looking statements, please see our most recent annual report on Form 10-K. Now, I'd like to turn the call over to Ron.

Thank you, Callan, and good morning. In Q1 2023, scenario generated $15.5 million in net revenue, representing a 99% increase from the prior year period. The first quarter of 2023 was another record quarter for Scenera, and March was the highest sales month in the company's history. We continued to see strong growth and accelerate sales, as well as increased sales from the products we licensed from Koch Biotech. Sales at Scendia were flat from Q4 to Q1 due to a stock out of Alisite product, which we'll discuss in greater detail later. The company had a net loss of $1.2 million compared to a net loss of $3.2 million for the prior year period. The lower loss was driven by higher sales and a change in the fair value of our earn-out liabilities. On March 16, 2023, we submitted to FDA a 510 pre-market notification for our precision healing multispectral imager. Zach will go into more detail on the imager's capabilities, but we believe that it's a critical component of our value-based strategy. Subject to the end of the quarter, the company received 510 clearance for BioServe's advanced surgical solution. This product, which was developed by our team at Rochelle, is expected to commercially launch in 2023. As we mentioned on our previous call, in the first quarter, we entered into a sales agreement with Cantor Fitzgerald for an ATM offering of our capital stock. We entered into this agreement for two purposes. The first was to raise capital for opportunistic partnerships and acquisitions, and the second was to increase the liquidity of our common stock. We currently intend to use the net proceeds we received from this offering to potentially fund acquisitions, further development of our products and technology pipeline, as well as clinical studies, Salesforce expansion, and for general corporate purposes. During the quarter, we chose to utilize our ATM, and over the course of 17 trading days, we received approximately $1 million in net proceeds. Sales were paused at the end of Q1. We could potentially reactivate the ATM if and when the management and board determined it's appropriate. Now, I'd like to ask Zach Fleming to discuss our business in more detail. Thank you.